Keros Therapeutics
KROS
107 hedge funds and large institutions have $731M invested in Keros Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 20 closing their positions.
55,700% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $3K
66% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 29
1.46% more ownership
Funds ownership: 75.81% → 77.26% (+1.5%)
13% less funds holding
Funds holding: 123 → 107 (-16)
19% less capital invested
Capital invested by funds: $901M → $731M (-$170M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
80% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$16.4M |
| 2 |
Morgan Stanley
New York
|
+$14.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.31M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$7.97M |
| 5 |
Millennium Management
New York
|
+$6.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$12M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.46M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$6.29M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.25M |
KROS Hedge Fund Activity: Q3 2023 in Review
107 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2023, worth a combined $731M — down 19% from $901M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KROS and 4 opened new positions — a net loss of 16 holders — while 29 trimmed existing stakes and 48 added.
The largest buyer was Woodline Partners, adding an estimated $16.4M. The largest seller was Fidelity Investments, cutting an estimated $17M.
- 107 institutional investors held Keros Therapeutics (KROS) as of Q3 2023, down from 123 in Q2 2023.
- Funds reported $731M of Keros Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
- 4 funds opened new Keros Therapeutics positions in Q3 2023 and 20 closed out, a net change of -16 holders.
- The largest Keros Therapeutics buyer in Q3 2023 was Woodline Partners, an estimated $16.4M added.
- The largest Keros Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2023.